Structure of the AbbVie BCL-2 inhibitor prodrug (ABBV-167)

venetoclax prodrug with reduced food effect

enhanced bioavailability in healthy volunteers

from venetoclax heterocycle N-alkylation

Mol. Cancer. Ther. Mar. 30, 2021

AbbVie, North Chicago, IL

The AbbVie BCL-2 inhibitor prodrug (ABBV-167) is a phosphate prodrug of venetoclax used for treatment of chronic lymphocytic leukemia (CLL). This molecule has an interesting prodrug mechanism, masking an…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.